| Continental Care And Rehabilitation | |
| 2400 Continental Dr, Butte, Montana 59701 | |
| (406) 723-6556 | |
| Name | Continental Care And Rehabilitation |
|---|---|
| Location | 2400 Continental Dr, Butte, Montana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 39.8% |
| Medicare ID (CCN) | 275103 |
| Legal Business Name | Sweetwater Butte Opco Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1003861899 |
| Organization Name | PEAK MEDICAL MONTANA OPERATIONS, LLC |
| Doing Business As | BUTTE CENTER |
| Address | 2400 Continental Dr, Butte, MT 59701 |
| Phone Number | 406-723-6556 |
News Archive
Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
The results of a unique study from the University of Gothenburg, Sweden, show that personality has an impact on how likely people are to take their medication. This is the first major study of its kind to be published in the online journal PloS ONE.
› Verified 4 days ago
| NPI Number | 1427537331 |
| Organization Name | BUTTE CARE HOLDINGS, LLC |
| Address | 2400 Continental Dr, Butte, MT 59701 |
| Phone Number | 406-723-6556 |
News Archive
Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
The results of a unique study from the University of Gothenburg, Sweden, show that personality has an impact on how likely people are to take their medication. This is the first major study of its kind to be published in the online journal PloS ONE.
› Verified 4 days ago
| NPI Number | 1679016596 |
| Organization Name | EMPRES AT BUTTE, LLC |
| Doing Business As | BUTTE HEALTH AND REHABILITATION CENTER |
| Address | 2400 Continental Dr, Butte, MT 59701 |
| Phone Number | 406-723-6556 |
News Archive
Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
The results of a unique study from the University of Gothenburg, Sweden, show that personality has an impact on how likely people are to take their medication. This is the first major study of its kind to be published in the online journal PloS ONE.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
The results of a unique study from the University of Gothenburg, Sweden, show that personality has an impact on how likely people are to take their medication. This is the first major study of its kind to be published in the online journal PloS ONE.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 5 |
| Total Amount of Fines in Dollars | $102072 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 6 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.13 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.81 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 22.22 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 5.66 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.95 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.19 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.01 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.25 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 73.6 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.95 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.65 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.46 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.63 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.99 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 61.75 | 82.93 |
News Archive
Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).
Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.
The results of a unique study from the University of Gothenburg, Sweden, show that personality has an impact on how likely people are to take their medication. This is the first major study of its kind to be published in the online journal PloS ONE.
› Verified 4 days ago
Copper Ridge Health And Rehabilitation Center Location: 3251 Nettie St, Butte, Montana 59701 Phone: (406) 723-3225 | |
Continental Care And Rehabilitation Location: 2400 Continental Dr, Butte, Montana 59701 Phone: (406) 723-6556 | |